新科学想法 › 学术文库 › 学术文献 › 浏览文献

Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration

yucloud 添加于 2012-8-9 11:03 | 1142 次阅读 | 0 个评论

作者
Ohr M, Kaiser PK
摘要
INTRODUCTION: Age-related macular degeneration (AMD) continues to be a leading cause of blindness worldwide. The neovascular form of the disease can lead to rapid and progressive vision loss. Vascular endothelial growth factor (VEGF) has emerged as a key target of treatment, with inhibitors of VEGF being shown to arrest the angiogenic process and avoid the visual damage typically associated with its presence. AREAS COVERED: This manuscript reviews the treatment history for wet AMD and examines aflibercept , a new, fully human, recombinant fusion protein designed to bind all isoforms of VEGF-A, as well as placental growth factor (PGF), thereby inhibiting the binding and activation of VEGF receptors. EXPERT OPINION: The results of Phase I, II and III studies have proven aflibercept to be a safe and effective treatment for wet AMD. Recent results of Phase III studies demonstrate the efficacy of aflibercept, dosed every 8 weeks after three initial monthly doses, and show that this regimen is clinically equivalent to monthly ranibizumab therapy. Eylea (aflibercept) was approved by the FDA for the treatment of wet AMD on 18 November 2011.
详细资料
- 关键词: Animals; Clinical Trials as Topic; Humans; Intravitreal Injections; Macular Degeneration/*drug therapy; Neovascularization, Pathologic/drug therapy; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins/*administration & dosage
- 文献种类: Journal Article
- 期刊名称: Expert Opinion on Pharmacotherapy
- 期刊缩写: Expert Opin Pharmacother
- 期卷页: 2012年第13卷第4期 585-591页
- 地址: Cole Eye Institute, Cleveland Clinic, 9500 Euclid Ave, Desk i3, Cleveland, OH 44195, USA
- ISBN: 1465-6566
学科领域生物医药 » 药学
相关链接 DOI URL
yucloud 的文献笔记订阅